Apogee Therapeutics, Inc. (APGE) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.68
↑+39% vs avg
5yr avg: 4.09
30Y Low3.5·High5.1
ROE
↓
-31.6%
-1% vs avg
5yr avg: -31.2%
30Y Low-33%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
APGE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Apogee Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $5.8B | $4.6B | $2.5B | $1.4B | — |
| Enterprise Value | $5.7B | $4.5B | $2.4B | $1.3B | — |
| P/E Ratio → | -20.03 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 5.68 | 5.07 | 3.49 | 3.73 | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
APGE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
APGE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -31.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -31.6% | -31.6% | -33.2% | -32.2% | -28.0% |
| ROA | -30.3% | -30.3% | -31.5% | -30.3% | -26.2% |
| ROIC | -31.3% | -31.3% | -38.3% | -55.0% | — |
| ROCE | -34.9% | -34.9% | -39.2% | -35.6% | -21.6% |
APGE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $132M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.18 | -0.31 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -3.36 |
Net cash position: cash ($132M) exceeds total debt ($9M)
APGE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Apogee Therapeutics, Inc.'s current ratio of 26.57x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 19.38x to 26.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 26.57 | 26.57 | 18.55 | 19.38 | 15.24 |
| Quick Ratio | 26.57 | 26.57 | 18.55 | 19.38 | 15.24 |
| Cash Ratio | 26.17 | 26.17 | 18.23 | 19.24 | 15.22 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
APGE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Apogee Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $61M | $55M | $51M | $51M |
Peer Comparison
Compare APGE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 APGEYou | $6B | -20.0 | — | — | — | — | -31.6% | -31.3% | — |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 RXRX | $2B | -2.4 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 SNDX | $2B | -6.3 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See APGE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APGE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APGE vs REGN
Side-by-side business, growth, and profitability comparison vs Regeneron Pharmaceuticals, Inc..
Start ComparisonAPGE — Frequently Asked Questions
Quick answers to the most common questions about buying APGE stock.
What is Apogee Therapeutics, Inc.'s P/E ratio?
Apogee Therapeutics, Inc.'s current P/E ratio is -20.0x. This places it at the 50th percentile of its historical range.
What is Apogee Therapeutics, Inc.'s ROE?
Apogee Therapeutics, Inc.'s return on equity (ROE) is -31.6%. The historical average is -31.2%.
Is APGE stock overvalued?
Based on historical data, Apogee Therapeutics, Inc. is trading at a P/E of -20.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.